Skip to content

Efficacy and safety of orlistat in obese patients with hyperlipidemia

A controlled randomized trial of the use of orlistat and simvastatin treatment in obesity combined hyperlipidemia patients for safety and efficacy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17010887
Enrollment
Unknown
Registered
2017-03-16
Start date
2017-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity complicated by hyperlipidemia

Interventions

1:Simvastatin group
2:Orlistat-Simvastatin group

Sponsors

Beijing Anzhen Hospital Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years old; 2. Body mass index (BMI) 24-40; 3. Total cholesterol(TC) =6.22 mmol/L; 4. Triglyceride(TG)=2.26 mmol/L; 5. High density lipoprotein cholesterol (HDL-c)<1.0 mmol/L; 6. Low density lipoprotein cholesterol (LDL-c)=3.12 mmol/L. Both 1 and 2at least one of 3.4.5.6 items at the same time.

Exclusion criteria

Exclusion criteria: 1. Weight loss or rise more than 4 kg in nearly three months, 2. Diabetes; 3. Patients with congenital heart disease, rheumatic heart disease, acute or chronic renal insufficiency, severe liver active disease; 4. Patients with a history of myocardial infarction or unstable angina within 3 months before research, 5. Patients with a history of recurrent gallstones or kidney stones, 6. Patients who had been diagnosed with postoperative intestinal adhesion, 7. Patients with peptic ulcer or malabsorption syndrome; 8. Patients with a history of pancreatitis; 9. ALT or AST ? 2.5 times of normal level; 10. Patients with malignant tumor and HIV positive; 11. Psychiatric patients; 12. Patients with a history of hyperthyroidism appetite and laxation drug abuse; 13. Subjects who accept other study drugs in recent three months; 14. Researchers think that the subject who are not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
Body weight;Body mass index (BMI);

Secondary

MeasureTime frame
Blood pressure;Heart rate;Total cholesterol(TC);Triglyceride(TG);High density lipoprotein cholesterol (HDL-c);Low density lipoprotein cholesterol (LDL-c);

Countries

China

Contacts

Public ContactWang Zuoguang

Beijing Anzhen Hospital, Capital Medical University

wyhhzq818@sina.com+86 010-64456462

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026